Bio-Reference Laboratories (BRLI +5.8%) shrugs off a negative article in The Street Sweeper yesterday to trade higher in spite posting a mixed FQ1 earnings report. The company beat on a per share basis but missed on its top line consensus as revenue was impacted from hurrican Sandy. Going forward the company reaffirms its guidance for FY13, still expecting net revenues to increase more than 15% and net income to increase by approximately 20%.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs